IL-18 Variant Polypeptides for Therapeutic Use
Summary
USPTO published patent application US20260092093A1 on April 2, 2026, disclosing engineered IL-18 variant polypeptides with mutations at positions G3, E6, D54, N91, C38, C68, C76, D98, S117, and C127. The variants demonstrate enhanced IL-18Rα binding and reduced IL-18BP binding compared to wild-type human IL-18 (SEQ ID NO: 1). Inventors include Min QIANG, Xi CHEN, Zhengyi WANG, Hui ZENG, Xin ZHENG, Fei ZHANG, Puwei YUAN, and Fan LIU, with original filing dated September 6, 2023.
What changed
The USPTO published international patent application US20260092093A1 disclosing novel interleukin-18 (IL-18) variant polypeptides for therapeutic use. The claimed variants comprise mutations at multiple positions relative to wild-type human IL-18 (SEQ ID NO: 1), specifically G3, E6, D54, N91, with additional可选 mutations at C38, C68, C76, D98, S117, and C127. The variants exhibit increased binding to IL-18Rα receptor while demonstrating substantially reduced binding to IL-18 binding protein (IL-18BP). The application covers nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of treatment using these variants. The inventors are Min QIANG, Xi CHEN, Zhengyi WANG, Hui ZENG, Xin ZHENG, Fei ZHANG, Puwei YUAN, and Fan LIU, with filing date September 6, 2023 and application number 19108967.
No immediate compliance action is required as this is a patent application publication rather than an issued regulation. Organizations developing IL-18 based therapeutics or related immunotherapies should monitor this application's prosecution status to assess potential freedom-to-operate implications. Competitors in the interleukin therapeutic space may need to evaluate whether their development programs could conflict with the disclosed variant compositions and therapeutic uses.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IL-18 VARIANT POLYPEPTIDES
Application US20260092093A1 Kind: A1 Apr 02, 2026
Inventors
Min QIANG, Xi CHEN, Zhengyi WANG, Hui ZENG, Xin ZHENG, Fei ZHANG, Puwei YUAN, Fan LIU
Abstract
Provided are interleukin 18 (IL-18) variant polypeptides that comprise mutation(s) at one or more of G3, E6, D54, and N91, wherein amino acid positions are relative to a wild-type human IL-18 set forth in SEQ ID NO: 1. Also provided are IL-18 variant polypeptide comprising (such as further comprising) at least one mutation at a residue selected from the group consisting of: C38, C68, C76, D98, S117, and C127, wherein the amino acid position is relative to a wild-type human IL-18 set forth in SEQ ID NO: 1. Also provided are IL-18 variant polypeptides bind IL-18Rα and exhibit substantially reduced binding to IL-18BP relative to the wild-type IL-18. Also provided are IL-18 variant polypeptides that exhibit increased binding IL-18Rα relative to the wild-type IL-18 and substantially reduced binding to IL-18BP relative to the wild-type IL-18. Also provided are related nucleic acids, vectors, host cells, methods of producing IL-18 variant polypeptides, pharmaceutical compositions comprising IL-18 variant polypeptides, and uses of such pharmaceutical compositions.
CPC Classifications
C07K 14/54 A61K 38/00 C07K 2319/30
Filing Date
2023-09-06
Application No.
19108967
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.